Cantor Fitzgerald L. P. Purchases New Stake in Teva Pharmaceutical Industries Ltd. $TEVA

Cantor Fitzgerald L. P. acquired a new position in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) during the third quarter, HoldingsChannel.com reports. The firm acquired 68,890 shares of the company’s stock, valued at approximately $1,392,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. AQR Capital Management LLC grew its holdings in Teva Pharmaceutical Industries by 24.6% in the 1st quarter. AQR Capital Management LLC now owns 23,955 shares of the company’s stock valued at $368,000 after buying an additional 4,732 shares in the last quarter. Focus Partners Wealth raised its holdings in shares of Teva Pharmaceutical Industries by 4.5% during the 1st quarter. Focus Partners Wealth now owns 40,074 shares of the company’s stock worth $616,000 after acquiring an additional 1,739 shares during the period. Geode Capital Management LLC boosted its position in shares of Teva Pharmaceutical Industries by 4.7% during the 2nd quarter. Geode Capital Management LLC now owns 9,629,526 shares of the company’s stock valued at $160,248,000 after acquiring an additional 434,918 shares during the last quarter. Creative Planning grew its holdings in shares of Teva Pharmaceutical Industries by 23.8% in the second quarter. Creative Planning now owns 56,164 shares of the company’s stock valued at $941,000 after purchasing an additional 10,784 shares during the period. Finally, Nomura Asset Management Co. Ltd. grew its holdings in shares of Teva Pharmaceutical Industries by 6.8% in the second quarter. Nomura Asset Management Co. Ltd. now owns 349,238 shares of the company’s stock valued at $5,853,000 after purchasing an additional 22,300 shares during the period. Institutional investors and hedge funds own 54.05% of the company’s stock.

Insider Activity

In other Teva Pharmaceutical Industries news, insider Eric A. Hughes sold 9,533 shares of the company’s stock in a transaction on Thursday, March 5th. The stock was sold at an average price of $31.67, for a total transaction of $301,910.11. Following the transaction, the insider directly owned 107,711 shares in the company, valued at $3,411,207.37. This represents a 8.13% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Eliyahu Sharon Kalif sold 345,810 shares of the firm’s stock in a transaction on Thursday, February 26th. The stock was sold at an average price of $33.64, for a total value of $11,633,048.40. Following the transaction, the executive vice president owned 57,478 shares of the company’s stock, valued at approximately $1,933,559.92. This represents a 85.75% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 858,799 shares of company stock worth $28,185,035 in the last three months. 0.49% of the stock is currently owned by corporate insiders.

Teva Pharmaceutical Industries Stock Down 1.6%

Shares of TEVA opened at $29.60 on Thursday. The company’s 50-day moving average price is $32.78 and its 200 day moving average price is $26.92. Teva Pharmaceutical Industries Ltd. has a 12-month low of $12.47 and a 12-month high of $37.35. The company has a current ratio of 1.04, a quick ratio of 0.80 and a debt-to-equity ratio of 1.89. The firm has a market cap of $34.04 billion, a P/E ratio of 24.67, a price-to-earnings-growth ratio of 10.07 and a beta of 0.72.

Teva Pharmaceutical Industries (NYSE:TEVA) last announced its earnings results on Wednesday, January 28th. The company reported $0.96 earnings per share for the quarter, topping the consensus estimate of $0.65 by $0.31. Teva Pharmaceutical Industries had a net margin of 8.16% and a return on equity of 46.28%. The company had revenue of $4.71 billion during the quarter, compared to analyst estimates of $4.36 billion. During the same quarter last year, the firm posted $0.71 earnings per share. Teva Pharmaceutical Industries’s revenue was up 11.4% compared to the same quarter last year. Teva Pharmaceutical Industries has set its FY 2026 guidance at 2.570-2.770 EPS. On average, sell-side analysts forecast that Teva Pharmaceutical Industries Ltd. will post 2.5 earnings per share for the current year.

Analysts Set New Price Targets

Several research firms recently issued reports on TEVA. Wall Street Zen upgraded shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research report on Saturday, January 31st. Jefferies Financial Group increased their price target on shares of Teva Pharmaceutical Industries from $29.00 to $40.00 and gave the company a “buy” rating in a research note on Tuesday, January 6th. Piper Sandler restated an “overweight” rating and set a $41.00 price target (up from $40.00) on shares of Teva Pharmaceutical Industries in a report on Wednesday, March 4th. JPMorgan Chase & Co. lifted their price target on shares of Teva Pharmaceutical Industries from $28.00 to $35.00 and gave the company an “overweight” rating in a research report on Tuesday, December 16th. Finally, The Goldman Sachs Group upped their price objective on Teva Pharmaceutical Industries from $36.00 to $45.00 and gave the company a “buy” rating in a report on Monday, February 9th. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $37.67.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) is an Israeli multinational pharmaceutical company and one of the world’s largest manufacturers of generic medicines. The company’s core activities include the development, production and marketing of generic pharmaceuticals alongside a portfolio of specialty branded medicines. Teva supplies finished dosage forms and active pharmaceutical ingredients (APIs) to markets around the globe and operates manufacturing and research facilities in multiple countries.

Teva’s product range covers oral solids, injectables, inhalation products and other dosage forms across therapeutic areas such as central nervous system disorders, respiratory, oncology, pain and infectious disease.